Surgical Treatment of Pancreatic Neuroendocrine Tumours - Clinical Experience

• Authors: Beata Jabłońska , Daria Dranka-Bojarowska , Hanna Palacz , Adam Lewiński , Paweł Lampe
• Languages of publication: EN

Abstracts

EN

The aim of the work was the clinical characteristics and analysis of preliminary results for surgical treatment of pancreatic neuroendocrine tumors (PNETs), based on own material.Material and methods. In the period from 2005 to 2009, in the Department of Gastrointestinal Surgery, Silesian Medical University in Katowice, there were 27 patients (15 males and 12 females) treated surgically for pancreatic neuroendocrine tumours, constituting 65.86% (27/41) of all gastroenteropancreatic neuroendocrine tumours. Prior to the surgery, the following diagnostic examinationswere performed: laboratory tests and imaging examinations (abdominal ultrasound and CT scan). The following tumour localisation was established: head of the pancreas - 14, body of the pancreas - 4, tail of the pancreas - 5, body and tail of the pancreas - 1, retroperitoneal space - 4. There were found 24 (88.89%) primary tumours and 3 (11.11%) recurrences. The following methods of surgical treatment were applied: pancreatoduodenectomy - 11, distal pancreatic resection with splenectomy - 6, middle segment resection with anastomosis between the pancreatic tail and jejunal loop: Roux-Y procedure - 1, pancreatic resection by Beger procedure - 1, pancreatic head and body resection with splenectomy - 1, tumour enucleation or local excision - 4, exploratory laparotomy with specimen collection - 3.Results. The mean hospitalisation period was 25 days (4-78 days). The mean procedure duration was 4.2 hours (1.15-9.15 hours). Early post-operative complications were observed in 10 patients (37.04%). The following early complications were observed: intra-abdominal abscess - 2, wound suppuration - 2, pancreatic fistula - 1, acute pancreatitis - 1, pancreaticojejunal anastomosis leak - 1, peritoneal cavity haemorrhage - 1, acute cholangitis - 1, adhesion obstruction - 1, subobstruction - 1, portal vein thrombosis - 1, sepsis - 1, fluid in pleural cavity - 1, acute heart failure - 1. There were performed 2 (7.41%) repeat surgeries: one due to adhesion obstruction and one due to peritoneal cavity haemorrhage. Death of 1 patient (3.71%) was recorded in the post-operative period due to acute heart failure.Conclusions. Pancreatic neuroendocrine tumours constituted the majority of gastroenteropancreatic neuroendocrine tumours in the analysed patient group. Most commonly, PNETs were localised in the head of the pancreas. In the presented material, the mortality rate does not exceed 4%, similarly as in other renowned centres.

Keywords

EN

neuroendocrine tumours; pancreas

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2011
• Volume: 83
• Issue: 4
• Pages: 216-222

Dates

published

1 - 4 - 2011

online

7 - 6 - 2011

Contributors

author

Beata Jabłońska

• Department of Gastrointestinal Surgery, Silesian Medical University in Katowice

author

Daria Dranka-Bojarowska

• Department of Gastrointestinal Surgery, Silesian Medical University in Katowice

author

Hanna Palacz

• Department of Gastrointestinal Surgery, Silesian Medical University in Katowice

author

Adam Lewiński

• Department of Gastrointestinal Surgery, Silesian Medical University in Katowice

author

Paweł Lampe

• Department of Gastrointestinal Surgery, Silesian Medical University in Katowice

References

• Lampe P, Jabłońska B: Postąpowanie chirurgiczne w guzach endokrynnych trzustki. Red. Kos-Kudła B. W: Guzy neuroendokrynne układu pokarmowego. Gdańsk, Via Medica; 2010; 115-26.
• Solcia E, Klöppel G, Sobin LH et al.: Histological Typing of Endocrine Tumors. WHO International Histological Classification of Tumors. 2nd ed. Berlin: Springer; 2000: 56-70.
• Travis WD, Brambilla E, Muller-Hermlink HK et al.: World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004: 196-98.
• Öberg K, Astrup L, Eriksson B et al.:. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004; 43: 617-25.[Crossref][PubMed]
• Öberg K, Kvols L, M. Caplin M et al.: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 2004; 15: 966-73.[Crossref]
• Nicholls A: Simple adenoma of pancreas arising from an islet of Langerhans. J Med Res 1902; 8: 385-95.
• Kos-Kudła B, Bolanowski M, Hubalewska-Dydejczyk A et al.: Guzy endokrynne trzustki (zasady postąpowania rekomendowane przez Polską Sieć Guzów Neuroendokrynnych). Endokrynol Pol 2008; 59 (1): 68-86.
• Ong SL, Garcea G, Pollard CA et al.: A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology 2009; 9: 583-600.[WoS][Crossref][PubMed]
• Ito H, Abramson M, Ito K et al.: Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. J Gastrointest Surg 2010; 14(5): 891-98.
• Scarpa A, Mantovani W, Capelli P et al.: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23(6): 824-33.[PubMed][WoS][Crossref]
• Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D et al.: Zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych). Endokrynol Pol 2008; 59 (1): 41-56.
• O'Grady HL, Conlon KC: Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2008; 34(3): 324-32.[Crossref]
• Anlauf M, Sipos B, Kloppel G: Tumors of the endocrine pancreas. Pathologe 2005; 26: 46-51.[Crossref][PubMed]
• Imamura M: Surgical Treatment. W: Beger HG, Warshaw A, Buchler M i wsp. ed: The Pancreas. 2nd edition. Massachusetts: Blackwell Publishing, 2008; 818-22.
• Imamura M: Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(36): 4519-25.[Crossref][PubMed]
• Kaemmerer D, Prasad V, Daffner W et al.: Neo-adjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15(46): 5867-70.[Crossref][WoS]
• Nakeeb A: Laparoscopic pancreatic resection. W: John L. Cameron, ed: Current surgical therapy. 9th ed., Philadelphia, Mosby, 2008; 1346-51.
• Grant CS. Insulinoma. W: Doherty GM, Skogseid B, ed: Surgical Endocrinology. Philadelphia: Lippincott Williums & Wilkins, 2001: 345-60.
• Falconi M, Bettini R, Boninsegna L et al.: Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP 2006; 7(1): 150-56.[PubMed]
• Alexakis N, Neoptolemos JP: Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2008; 22(1): 183-205.[Crossref][PubMed]
• Müller MW, Friess H, Kleeff J et al.: Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. Ann Surg 2006; 244(6): 909-18.
• Crippa S, Bassi C, Warshaw AL et al.: Middle pancreatectomy: indications, short- and long-term operative outcomes. Ann Surg 2007; 246(1): 69-76.[WoS][Crossref]
• Huang H, Dong X, Gao SL, et al.: Conservative resection for benign tumors of the proximal pancreas. World J Gastroenterol 2009; 15(32): 4044-48.[Crossref][WoS]
• Sperti C, Beltrame V, Milanetto AC et al.: Parenchyma-sparing pancreatectomies for benign or border-line tumors of the pancreas. World J Gastrointest Oncol 2010; 2(6): 272-81.
• Kennedy TJ, Cassera MA, Wolf R et al.: Surgeon volume versus morbidity and cost in patients undergoing pancreaticoduodenectomy in an academic community medical center. J Gastrointest Surg 2010; 14(12): 1990-96.[Crossref][WoS]
• Schmidt CM, Turrini O, Parikh P et al.: Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreatico-duodenectomy: a single-institution experience. Arch Surg 2010; 145(7): 634-40.[Crossref]
• Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141(8): 765-69.
• Gao C, Fu X, Pan Y, Li Q: Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg 2010; 27(3): 197-204.[Crossref][PubMed]
• Butturini G, Marcucci S, Molinari E et al.: Complications after pancreaticoduodenectomy: the problem of current definitions. J Hepatobiliary Pancreat Surg 2006; 13(3): 207-11.
• Butturini G, Daskalaki D, Molinari E et al.: Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008; 15(3): 247-51.

Identifiers

DOI

10.2478/v10035-011-0033-5